English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

SDS Biotech’s recorded sales of 2,431 million yen in Q1 FY 2018-19qrcode

Aug. 10, 2018

Favorites Print
Forward
Aug. 10, 2018

Follow


Net sales of SDS Biotech for the first quarter of the fiscal year ending March 2019, were 2,431 million yen, operating income was 106 million yen, ordinary income was 127 million yen and net income came to 21 million yen. 
 
According to the company, they transitioned to non-consolidated accounting from the settlement of accounts for the fiscal year ended March 31, 2018, they did not analyze figures in the same period the previous year and changes compared to the same period the previous year. 
 
Fungicide
Net sales for the period under review were 586 million yen. This mainly products were Daconill products (technical and formulation). Demand for Daconil-related products (chlorothalonil), SDS’ mainstay products, has continued to grow globally, the company cannot respond to the demand due to the effects of the fire incident at Yokohama Works, which occurred in February this year. 
 
Paddy herbicide
Net sales for the period under review were 500 million yen. This mainly products were Diamuron technical, Benzobicyclon technical and Cafenstrole technical for Japanese market. 
 
Greenery-related products
Net sales for the period under review were 709 million yen. This mainly products were Karbutilate products (technical and formulation) for Japanese market, and Dacthal technical for overseas market. 
 
Insecticides
Net sales for the period under review were 135 million yen. This mainly products were D-D products and biological product (Tune-up WDG) for Japanese market. 
 
Others 
Net sales for the period under review were 499 million yen. This mainly products were Daconil raw material.

Outlook for the Fiscal Year Ending March 2019 
 
Regarding the earnings forecast for the fiscal year ending March 31, 2019, SDS is thoroughly investigating the impacts of a fire incident at Yokohama Works, which occurred on February 12, 2018. However, it is difficult to rationally estimate the impacts at this point, given that there are many unconfirmed elements that could affect earnings. 
 
Therefore, the company will announce the earnings forecast when the detailed investigation of the impacts of the fire incident at Yokohama Works is completed and it becomes possible to rationally estimate the impacts.
 
Source: SDS Biotech

0/1200

More from AgroNewsChange

Hot Topic More

I wanna post a press Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe AgroNews Daily Alert to send news related to your mailbox